Atrial Fibrillation
Conditions
Keywords
Cardiology
Brief summary
study to evaluate the performance of the CardiacSense1's embedded PPG under different environmental and physical conditions
Detailed description
The clinical study is a Prospective, Open, Single-Center, and Controlled Study to Evaluate the Performance of a PPG sensor in the CardiacSense1 device. The CardiacSense1 is a wrist worn device designed to detect atrial fibrillation (AF). The AF detection of the device is based on a portable photoplethysmograph (PPG) sensor that is designed for continuous heart rate monitoring. The photoplethysmograph is a noninvasive circulatory signal related to the pulsatile volume of blood in the tissue. Twenty (20) subjects (female and male) that do not suffer from atrial defibrillation and additional four (4) patients who are diagnosed as suffering from atrial fibrillation will be enrolled to the study. Comparison of CardiacSense1 PPG individual peak detection to the corresponding recorded activity of an FDA-cleared ECG Holter, on a beat-by-beat basis will be performed on the following conditions: All subjects will be exposed to 45 minutes of indoor standard office fluorescent light and 45 minutes to outdoor sunlight during mid-day. In addition, Subjects will be asked to walk for 1 minute once every 10 minutes and will be exposed to an indoor environment of 22±3 - 28±3 degree Celsius for 45 minutes and outdoor temperature of at least 15 degree Celsius, on the other 45 minutes. 4 Subjects will be tested in the following conditions: driving a car for 30 minutes; High wrist hair density subjects; Two subjects 65 y/o or older, two subjects 30 y/o or younger; Two subjects with BMI below 18.5 (underweight) and two subjects with BMI over 30 (Obesity); Two subjects with skin type 6 (Fitzpatrick) and two subjects with skin type 5; Four subjects with diagnosed persistent atrial fibrillation.
Interventions
DEVICEStudy Procedure for Participants That Were Not in the Driving Group
Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition: 1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius. 2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius. 3. Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor
DEVICEStudy Procedure for Participants That Were Included in the Driving Group
Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition: 1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius. 2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius. 3. Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor
Sponsors
CardiacSense Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Age of eighteen to eighty-five (18-85) years * Ability and willing to sign informed consent form * For subjects in groups other than Heart Arrhythmias- Self-declared not to be diagnosed with any arrhythmia * Compliance with hair, age, BMI skin and heart arrhythmia variables as defined above
Exclusion criteria
* Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints. * Subject with low perfusion indicated by the watch * Pregnant or breastfeeding woman (women of child-bearing potential must have a negative pregnancy test within screening period).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PPG individual peak detection | 90 Minutes | Comparison of CardiacSense1 PPG individual peak detection to the corresponding recorded activity of an FDA-cleared ECG Holter, on a beat-by-beat basis. |
| PPG and Holter ECG signals correlation | 90 Minutes | Evaluation of the correlation between PPG signals and Holter ECG signals with respect to R-R signal intervals. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| signal intensity under different conditions | 90 minutes | Examination of PPG signal optic parameters (LED current, LED intensity) and signal intensity under different conditions. |
| Adverse events | 90 minutes | Rate of Adverse events related or unrelated to the study device. |
Countries
Israel
Outcome results
None listed